Tailoring the number of consults based on HF severity, which can be assessed pragmatically, could pay dividends, say ...

While the results bolster efficacy, questions remain about high costs and other issues with the ATTR-CM therapies.

As in the SMART trial, early hemodynamic differences have yet to result in a clinical impact—but it may just be a matter of ...

The results have implications not only for resource-limited parts of the world, but also for wealthier countries, one expert ...

STEMI criteria alone aren’t perfect for identifying occluded arteries, but still some question the need for a new paradigm.

Trialists should focus less on physician-defined outcomes and more on what matters to patients, Mario Gaudino says.

In patients with venous thromboembolism (VTE) who are candidates for oral anticoagulation, apixaban results in fewer ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

The early impact of gestational diabetes, hypertensive disorders of pregnancy, and obesity appears to grow as kids age.

The findings highlight the importance of rheumatology, cardiology, and primary care working together to intervene early.

With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.